Neurodegeneration: Therapeutic Targets

Neurodegeneration is the progressive loss of structure or function of neurons, including neuronal death, and leads to several diseases, including Alzheimer’s and Parkinson’s. This feed focuses on therapeutic targets for neurodegenerative disorders.

November 11, 2019
Review

DNA double-strand breaks: a potential therapeutic target for neurodegenerative diseases

Chromosome Research : an International Journal on the Molecular, Supramolecular and Evolutionary Aspects of Chromosome Biology
Nidheesh ThadathilMohammad Moshahid Khan
November 9, 2019
Review

Butyrylcholinesterase: A Multifaceted Pharmacological Target and Tool.

Current Protein & Peptide Science
Zhe Ying HaKeng Yoon Yeong
March 14, 2020
Review
Open Access

Protein Phosphatase 2A as a Drug Target in the Treatment of Cancer and Alzheimer's Disease

Current Medical Science
Hui WeiRong Liu
June 9, 2020
Review
Open Access

Molecular Insight into the Therapeutic Promise of Targeting APOE4 for Alzheimer's Disease

Oxidative Medicine and Cellular Longevity
Abdullah Al MamunMohamed M Abdel-Daim
July 12, 2019
Case Report
Open Access

Atopic Dermatitis-Like Rash During Evolocumab Treatment of Familial Hypercholesterolemia

Journal of Nippon Medical School = Nippon Ika Daigaku Zasshi
Naoko Kanda, Fumitaka Okajima
June 23, 2019
Open Access

Recent advances in molecular therapies for neurological disease: triplet repeat disorders

Human Molecular Genetics
Pedro Gonzalez-Alegre
November 21, 2019

Destabilization of β-amyloid aggregates by thrombin derived peptide: plausible role of thrombin in neuroprotection

The FEBS Journal
Debashree DeDebasish Bhattacharyya
June 28, 2019

The Outliers: Metal-Mediated Radical Reagents for Biological Substrate Degradation

Accounts of Chemical Research
Meghan R PorterJeffrey M Zaleski
April 20, 2020
Review
Open Access

Cathepsin B in neurodegeneration of Alzheimer's disease, traumatic brain injury, and related brain disorders

Biochimica Et Biophysica Acta. Proteins and Proteomics
Vivian HookGregory Hook
June 9, 2020
Open Access

Inhibition of STAT3 phosphorylation attenuates impairments in learning and memory in 5XFAD mice, an animal model of Alzheimer's disease

Journal of Pharmacological Sciences
Moonseok ChoiHye-Sun Kim
May 12, 2020
Review

Inherited disorders of lysosomal membrane transporters

Biochimica Et Biophysica Acta. Biomembranes
Marjan Huizing, William A Gahl
September 27, 2019
Review
Open Access

A New Kid on the Block? Carbonic Anhydrases as Possible New Targets in Alzheimer's Disease

International Journal of Molecular Sciences
Gustavo ProvensiSilvia Fossati
December 17, 2019
Review
Open Access

Tau as a potential therapeutic target for ischemic stroke

Aging
Xin Chen, Hua Jiang
December 8, 2019
Review
Open Access

Mechanisms of immune evasion in bladder cancer

Cancer Immunology, Immunotherapy : CII
Paul L Crispen, Sergei Kusmartsev
June 5, 2019
Review

Recent Developments in LRRK2-Targeted Therapy for Parkinson's Disease

Drugs
Ye Zhao, Nicolas Dzamko
November 22, 2019
Open Access

Vitamin K1 As A Potential Molecule For Reducing Single-Walled Carbon Nanotubes-Stimulated α-Synuclein Structural Changes And Cytotoxicity

International Journal of Nanomedicine
Amitis NaskhiMojtaba Falahati

Sign up to follow this feed and discover related papers.

Related Feeds

3D Cellular Models of Brain and Neurodegeneration

Brain organoids are three-dimensional in vitro cellular models of the brain that can recapitulate many processes such as the neurodevelopment. In addition, these organoids can be combined with other cell types, such as neurons and astrocytes to study their interactions in assembloids. Disease processes can also be modeled by induced pluripotent stem cell-derived organoids and assembloids from patients with neurodegenerative disorders. Discover the latest research on the models here.

ALS & FTD: TDP-43

TAR DNA-binding protein 43 (TDP-43) is a pathological protein identified in sporadic Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD). Here are the latest discoveries pertaining to TDP-43 and these diseases.

ALS: Genetics

Amyotrophic Lateral Sclerosis (ALS) is a progressive neurodegenerative disorder characterized by muscle weakness. ALS is a genetically heterogeneous disorder with several causative genes. Here are the latest discoveries pertaining to the genetics of this disease.

ALS: Pathogenic Mechanisms

Amyotrophic Lateral Sclerosis is a progressive neurodegenerative disorder characterized by muscle weakness. Here is the latest research investigating pathogenic mechanisms that underlie this genetically heterogeneous disorder.

ALS: Phenotypes

Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disorder characterized phenotypically by progressive muscle weakness. Clinical phenotypes of ALS can be classified based on the pattern, level, and area of onset (e.g. bulbar, cervical, lumbar). Here is the latest research investigating phenotypes of ALS.

ALS: Prions

Prions are misfolded proteins which characterize several fatal neurodegenerative diseases. Prion-like mechanisms are associated with the pathogenesis of Amyotrophic Lateral Sclerosis (ALS). Here is the latest research on ALS and prions.

ALS: Stress Granules

Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disease characterized by cytoplasmic protein aggregates within motor neurons. TDP-43 is an ALS-linked protein that is known to regulate splicing and storage of specific mRNAs into stress granules, which have been implicated in formation of ALS protein aggregates. Here is the latest research in this field.

ALS: Therapies

Amyotrophic Lateral Sclerosis (ALS) is associated with the death of neurons that control voluntary muscles. This feed followes the latest research into therapies for this progressive neurodegenerative disease.

Age-related Dementia

Dementias are a group of conditions, including Alzheimer's disease, vascular dementia, and frontotemporal dementia, characterized by deficiencies in cognitive abilities. Age-related dementia refers to dementias that occur in older individuals, usually 60+ years old, in contrast to early-onset dementia. Follow the latest research on age-related dementia here.

Alexander Disease

Alexander disease is a rare leukodystrophy caused by mutations in the astrocyte-specific intermediate filament protein glial fibrillary acidic protein (GFAP). Here is the latest research on this disease.

© 2021 Meta ULC. All rights reserved
/feed-previews/therapeutic-targets-for-neurodegeneration/ed37b9b8-3b0d-4d92-bd38-aa13d612c1ac